


HoloEye AI & ELPISEREMO Unveil AI-Driven Biological Artifactual Model to Select Oocytes with High Pregnancy Success Rate

HoloEye AI and ELPISEREMO Unveil Revolutionary Holographic-AI + Camera Driven By Biological Artifactual Model to Select Eggs with High Pregnancy Success Rates

PRINCETON, NEW JERSEY, USA, February 1, 2024 /EINPresswire.com/ -- [HoloEye.AI](#), a [ThirdEye Gen](#) spinoff, and [ELPISEREMO](#) proudly announces the ground-breaking launch of the world's first artificial intelligence-powered Smart Glasses + OculiDeus™ AI camera ecosystem of Holographic Biological Intelligence, enabling any embryologists, or a personalized AI-driven super intelligent holographic assistant, to make precise egg selections for Reproductive Genetic Innovations East (RGI-EAST).



HOLOEYE AI Holographic Super Biological ARTIFACTUAL Model

“

ELPISEREMO and HoloEye AI Holographic AI Glasses Powered by Biological Artifactual Model to augment in-vitro fertilization and human reproduction.” said James Ryan, CEO of ELPISEREMO.”

James Ryan

“We have about thirty trillion cells in our body which dynamically interact with our organ systems, organs, tissue, and cells. They exhibit complex patterning of gene and protein expression to execute their specific functions. In an effort to decipher this complex system language we developed a high-resolution Hyperspectral machine vision camera called OculiDeus™, which is powered by our proprietary Biological Artifactual Intelligence Model (BAiM), to harvest and analyze oscillatory patterns of biophotonic activity emissions from cells, tissues, and organs in real time, providing unprecedented insight into human body health or ill health. OculiDeus™ was born.” said Prof. Carlo

Ventura, CSO of HOLOEYE AI+ and ELPISEREMO.

"Using HoloEye AI OculiDeus™ ecosystem, the accuracy of predicting pregnancy success rate during infertility treatment will be greatly improved. Infertile Couples could preserve their quality viable eggs with a higher pregnancy success rate, rather than freezing eggs blindly.

Reproductive Genetic Innovations East (RGI EAST) will be utilizing OculiDeus™ AI during infertility treatment for viable egg selection and egg banking. ELPISEREMO team is working to improve tools and strategies to optimize in-vitro fertilization and human reproduction." said James Ryan, CEO of ELPISEREMO.

The collaboration between HoloEye.AI, ELPISEREMO, and RGI EAST brings

together a world leading trans-disciplinary team with decades of expertise in immersive technology, molecular cell and developmental biology, Physics, bio-chemistry, embryo cellular and genetics prenatal diagnosis detection of genetic and chromosomal disorders, computer vision, and precision bioengineering, delivering unprecedented benefits to infertility patients globally. This collaboration's valuation holds the potential to reach multiple billions.

OculiDeus™ is an advanced high-resolution hyperspectral camera vision system - with a myriad of optical sensors, which accelerates diagnostic accuracy and precision assessment of human cells, eggs (oocytes), tissue and organs, molecular signature insights, which is powered by a groundbreaking Proprietary Biological Artificial Intelligence Model (BAiM) to significantly boosts performance.

Nick Cherukuri, speaking on the collaboration, expressed his enthusiasm for the accelerated growth of HoloEye AI. "These collaborations represent the future of medical advancements with AI/MR, offering limitless possibilities for addressing global challenges of population stagnation, as well as Alzheimer's, Depression, Longevity, and Population Growth," he said. "We eagerly anticipate expanding our global subscriber base by welcoming additional partners in the medical field."

ABOUT HoloEye AI

HoloEye.AI, a ThirdEye Gen spinoff, is a transformative AI Biological Intelligence Company at the forefront of augmenting best-in-class, or first-in-class, pipeline of curative treatment modalities,



ELPISEREMO, a Precision Bioengineering
Regenerative-Medicine Technology Company



ThirdEye Gen 20+ years of mixed reality development
experience for the Department of Defense

assisted reproductive technologies, including pioneering technological advancements in entertainment and education. With a relentless focus on innovation, HoloEye AI specializes in the accelerated development and delivery of cutting-edge AI biotech healthcare products that harness the power of artificial intelligence to address challenges and promote wellbeing and healing in individuals.

Media Contact

For questions please contact
contact@holoeye.ai

ABOUT ELPISEREMO

ELPISEREMO is a precision bioengineering regenerative-medicine company whose platform technology precisely targets, harnesses and instructs the body's own tissue-resident cells, to produce nearly any therapeutic and regenerative protein, in place, with on/off precision, without the need to inject small-molecule drugs, mRNA, stem cells, or chemicals. ELPISEREMO mission is to accelerate delivery of the best-in-class, or first-in-class, pipeline of curative treatment modalities for those suffering with high unmet medical needs from a wide-range of devastating diseases, dysfunctions and disorders for which there is no cure.

<https://www.elpiseremo.com>

Contacts: James Ryan, CEO
Email: jr@elpiseremo.com
contact@rgiscience-east.com

<https://www.rgiscience-east.com/>

ABOUT THIRDEYE GEN

ThirdEye Gen is a leader in providing a complete digital end-to-end eco-system of fully integrated products in Artificial Intelligence/Mixed Reality. Its products include a robust portfolio of industry-specific SaaS enterprise AI/MR applications and associated hardware. ThirdEye's history includes over 20 years of delivering innovative, effective and efficient mixed reality products and solutions to the US Government and the Department of Defense.

For more information, visit www.thirdeyegen.com.

James Ryan
ELPISEREMO
[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/685373020>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.